Advertisement
Screener

MapLight Therapeutics, Inc. (MPLT) Graph

MPLT Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $53.44M; Operating expenses $63.55M; Net income -$60.19M.
  • 2026-03-31: Research and development $53.68M; Operating expenses $64.50M; Net income -$60.67M.
  • 2025-12-31: Research and development $64.62M*; Operating expenses $83.38M*; Net income -$79.55M*.
  • 2025-09-30: Research and development $27.09M; Operating expenses $31.50M; Net income -$29.42M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$53.44M$63.55M-$60.19M
2026-03-31$53.68M$64.50M-$60.67M
2025-12-31$64.62M*$83.38M*-$79.55M*
2025-09-30$27.09M$31.50M-$29.42M
2025-06-30$26.85M$30.66M-$29.84M
2025-03-31$19.79M$23.54M-$22.34M
2024-09-30$16.81M$20.89M-$19.02M
2024-06-30(m)(m)-$18.40M
2024-03-31(m)(m)-$18.93M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$107.12M$128.05M-$120.86M
2025-06-30$46.63M$54.21M-$52.19M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesNet income
2025-09-30$73.73M$85.71M-$81.60M
2024-09-30$47.81M$60.17M-$56.35M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesNet income
2025-12-31$138.35M$169.08M-$161.15M
2024-12-31$68.52M$82.95M-$77.58M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53